Drug safety check for rare blood disorder
NCT ID NCT06039020
Summary
This study aims to confirm the safety of the drug ATGAM for patients in Japan who have moderate to severe aplastic anemia, a rare condition where the body stops producing enough new blood cells. It will observe a small group of patients for 6 months to monitor for any side effects or adverse reactions related to the treatment. The main goal is to understand how safe the drug is when used in real-world medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.